TCTR20240405005已完成不适用
First-Line Immunosuppressive Therapies for Acquired Hemophilia A: A 25-year Cohort Experience and Network Meta-Analysis
/A0 个研究点目标入组 76 人开始时间: 2024年4月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 100 Years（—）
- 性别
- All
入选标准
- •Newly diagnosed acquired hemophilia patients age 18 years old and above
排除标准
- •Congenital hemophilia with inhibitor
研究者
相似试验
终止
不适用
A clinical trial to evaluate the effect of Losartan in early IgA nephropathy patientsDiseases of the genitourinary systemKCT0002916Ewha Womans University Medical Center174
已完成
不适用
A pharmacogenetic approach to immunosuppression for renal transplantatioISRCTN39668614Record Provided by the NHSTCT Register - 2007 Update - Department of Health (UK)100
招募中
不适用
Development of new approaches for immunotherapy of non-small cell lung cancerC34Malignant neoplasm of bronchus and lungDRKS00029641Molekulare PneumologieUniversitätsklinikum Erlangen
进行中（未招募）
不适用
Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy - STOP IgAEUCTR2007-000871-41-DERWTH Aachen148
尚未招募
不适用
Administration of immune checkpoint inhibitors through an elastomeric pump. A patient preference study and cost analysis.Solid tumors for which nivolumab or pembrolizumab monotherapy has an EMA approved indication. This includes (but is not limited to) melanoma, renal-cell cancer, NSCLC and head and neck cancer.NL-OMON25676Erasmus MC390